CARAFATE (sucralfate) by AbbVie is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. First approved in 1981.
Drug data last refreshed 1m ago · AI intelligence enriched 2d ago
CARAFATE (sucralfate) is an oral aluminum complex that accelerates healing of duodenal ulcers through local cytoprotective action. It forms an ulcer-adherent complex that protects the ulcer site from acid, pepsin, and bile salts while minimally being absorbed systemically. The mechanism involves barrier formation, pepsin inhibition, and bile salt adsorption at the ulcer site.
Product is approaching loss of exclusivity with modest Part D spending ($2M), signaling a mature, stable franchise with limited growth opportunities and likely contracted team infrastructure.
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…
Aluminum Complex
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CARAFATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CARAFATE offers limited career growth opportunities given its approaching loss of exclusivity, minimal clinical pipeline, and declining market presence reflected in zero linked job openings. Roles available are primarily defensive, maintenance-focused positions in market access and legacy brand management rather than innovation-driven opportunities.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo